Precision medicine in idiopathic pulmonary fibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Circulating Biomarkers for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis: Insights into Precision Medicine.Lung · 2026
   Review
2. Precision medicine advances in idiopathic pulmonary fibrosis.EBioMedicine · 2023
   Review
3. The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study.Respiratory research · 2022
   Observational
4. CD71American journal of respiratory and critical care medicine · 2019
   Article
5. Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?Expert review of respiratory medicine · 2018
   Article
6. Towards a global initiative for fibrosis treatment (GIFT).ERJ open research · 2017
   Article
7. Update in Interstitial Lung Disease 2016.American journal of respiratory and critical care medicine · 2017
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as